Brii Biosciences (HKSE:02137) Operating Cash Flow per Share : HK$-0.89 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Operating Cash Flow per Share?

Brii Biosciences's operating cash flow per share for the six months ended in Dec. 2023 was HK$-0.36. Brii Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.89.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Brii Biosciences's Operating Cash Flow per Share or its related term are showing as below:

HKSE:02137' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -93.3 Med: -51.45 Max: -9.6
Current: -9.6

During the past 5 years, Brii Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -9.60% per year. The lowest was -93.30% per year. And the median was -51.45% per year.

HKSE:02137's 3-Year OCF Growth Rate is ranked worse than
66.15% of 1235 companies
in the Biotechnology industry
Industry Median: 3.4 vs HKSE:02137: -9.60

Brii Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Brii Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Operating Cash Flow per Share Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.11

-0.68

-2.45

-0.77

-0.89

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial				-0.47	-0.44	-0.35	-0.53	-0.36

Competitive Comparison of Brii Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Brii Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Price-to-Operating-Cash-Flow falls into.

Brii Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Brii Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-649.72	/	728.100
	=	-0.89

Brii Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-262.784	/	728.712
	=	-0.36

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.89

Brii Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines